Table 4 Predicted fatty acid synthesis related MOAs of falcarinol and panaxydol using PASS program
Treatment | Paa | Pib | Biological activity |
|---|---|---|---|
Falcarinol | 8.2E-01 | 8.0E-03 | Alkyl-acetyl-glycero-phosphatase inhibitor |
8.0E-01 | 5.0E-03 | Fatty-acyl-CoA synthase inhibitor | |
6.9E-01 | 1.2E-02 | Lipid metabolism regulator | |
6.2E-01 | 9.0E-03 | Phosphatidyl-glycero-phosphatase inhibitor | |
4.5E-01 | 4.3E-02 | Alkenyl-glycero-phospho-ethanolamine hydrolase inhibitor | |
3.6E-01 | 1.3E-02 | Cyclopropane-fatty-acyl-phospholipid synthase inhibitor | |
Panaxydol | 6.7E-01 | 2.4E-02 | Alkyl-acetyl-glycero-phosphatase inhibitor |
6.7E-01 | 1.6E-02 | Fatty-acyl-CoA synthase inhibitor | |
6.6E-01 | 1.4E-02 | Lipid metabolism regulator | |
3.4E-01 | 3.6E-02 | Phosphatidyl-glycero-phosphatase inhibitor | |
3.8E-01 | 6.5E-02 | Alkenyl-glycero-phospho-ethanolamine hydrolase inhibitor | |
2.7E-01 | 3.7E-02 | Cyclopropane-fatty-acyl-phospholipid synthase inhibitor |